Business
BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
MINNEAPOLIS, May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy
About this update from Bio-techne Corp
[{"type":"text","content":"MINNEAPOLIS, May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.\nBio-Techne's booth (#1627) will feature our market-leading portfolio of high-quality life science research use only (RUO) and Good Manufacturing Practice (GMP) reagents, immunoassays, automated proteomic analytical instruments, and multi-omics solutions for accelerating cell and gene therapy development and manufacturing. We will also feature our \"Immune Cell Therapy Workflow\" multimedia experience, which enables attendees to explore how Bio-Techne's solutions streamline and accelerate the immune cell processing workflow.\nBio-Techne will host three speaker sessions during the conference, featuring both internal experts and customer case studies. The topics covered will include characterizing biodistribution and safety of cell and gene therapies, protein analytics strategies for gene therapy, and advancements in closed systems and non-viral cell engineering for immune cell therapy manufacturing.\nAdditionally, several Bio-Techne scientists will present posters highlighting our in-house studies in the areas of immune cell culture, automated spatial multi-omics, and protein or viral vector characterization. These include investigations into the efficient activation and expansion of human T cells for CAR-T therapy, RNA/protein ISH imaging of gene therapy biodistribution and persistence, and the multiparameter characterization of adeno-associated virus capsids.\n\"We are proud to support the advancement of cell and gene therapy research, development and manufacturing with our robust portfolio of innovative tools, reagents and workflow solutions,\" said Kim Kelderman, Bio-Techne's President and Chief Executive Officer. \"Bio-Techne's portfolio plays a critical role in the development of next-generation cell and gene therapies. Our broad presence at ASGCT will showcase the many roles Bio-Techne plays in catalyzing advances in science and medicine, and ultimately enabling patients to live healthier and longer lives.\"\nBio-Techne Presentations:Novel RNAscope™ Multi-omics Spatial Approach to Characterize Biodistribution and Safet...